ULINASTATIN

Ulinastatin is an active ingredient also recognised as a urinary trypsin inhibitor (UTI). The medication is used in certain countries for its anti-inflammatory and immunomodulatory properties. Originally isolated from human urine, it has undergone study for potential therapeutic applications.

Ulinastatin treats acute pancreatitis, sepsis, and acute respiratory distress syndrome (ARDS).

Ulinastatin is administered intravenously (vein injection) under medical supervision. Your healthcare professional will determine the specific dosage and administration guidelines based on your condition and needs.

Ulinastatin may cause side effects, including nausea, vomiting, diarrhea, skin rashes, headache, injection site reactions, and in rare cases, severe allergic reactions or anaphylaxis; patients should seek immediate medical attention if they experience any signs of a severe allergic reaction such as difficulty breathing, swelling of the face or throat, hives, or itching.

Ulinastatin's impact on patients with liver impairment is not well-established. The safety during pregnancy and breastfeeding is not fully established. intravenous administration of may lead to fluid overload, especially in patients with existing heart or kidney conditions. This medication’s immunomodulatory effects could increase the risk of infections. It may cause a decrease in platelet counts (thrombocytopenia) in some patients. It may impact on the central nervous system may cause dizziness, headache, or other neurological symptoms in some individuals. Patients with pre-existing autoimmune disorders should be closely monitored during treatment. The immunomodulatory effects of this medication may influence autoimmune conditions.

Caution is advised when using the medication in individuals with liver conditions, and close monitoring may be necessary. Pregnant or breastfeeding individuals should use the medication only if needed and under the supervision of a healthcare professional. Careful fluid management and monitoring are essential during treatment. Patients should be monitored for signs of new or worsening infections during therapy. Regular blood tests to monitor platelet levels may be necessary, especially in those with a history of bleeding disorders.

Patients with known hypersensitivity to ulinastatin or any of its components must not use this medication. Regular monitoring of renal and hepatic function is essential, with dose adjustments considered necessary for patients with impaired organ function. Caution is advised during pregnancy and breastfeeding, and the medication should be used only when medically indicated and under medical supervision. Close monitoring for signs of allergic reactions, infections, and alterations in blood counts is recommended. Patients with a history of gastrointestinal or bleeding disorders require close monitoring during treatment. All medical conditions and concurrent medications should be discussed with the treating physician to ensure safe and effective use of this medication.

Bharat Serums and Vaccines Limited, [Accessed on 27th July 2023], https://www.bharatserums.com/assets/pdf/products/U-Tryp(Liquid).pdf Qiancheng Xu et al; Ulinastatin is effective in reducing mortality for critically ill patients with sepsis: a causal mediation analysis; Scientific Reports; [Published on 25/09/2018]; [Accessed on 27/07/2023]; http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6156583/ Ling-Zhang wang et al; Effect of ulinastatin on serum inflammatory factors in Asian patients with acute pancreatitis before and after treatment: a meta-analysis; International Journal of Clinical Pharmacology and Therapeutics; [Published on Nov 2016]; [Accessed on 27/07/2023]; https://pubmed.ncbi.nlm.nih.gov/27569736/